Skip to main content
Linda Vahdat, MD, Oncology, Lebanon, NH

Linda T. Vahdat MD MBA

Breast Cancer


Chief of Cancer Services Memorial Sloan Kettering -Norwalk Hospital Partnership Professor of Medicine, Weill Cornell medicine

Join to View Full Profile
  • 1 Medical Center DrLebanon, NH 03756

  • Phone+1 603-650-5747

Dr. Vahdat is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Massachusetts Institute of Technology, Sloan School of Management
    Massachusetts Institute of Technology, Sloan School of ManagementMBA, Business, 2012 - 2014
  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1991 - 1994
  • Icahn School of Medicine at Mount Sinai/Mount Sinai Hospital
    Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1987 - 1990
  • Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount SinaiClass of 1987

Certifications & Licensure

  • NH State Medical License
    NH State Medical License 2022 - 2026
  • VT State Medical License
    VT State Medical License 2023 - 2026
  • NY State Medical License
    NY State Medical License 1988 - 2025
  • CT State Medical License
    CT State Medical License 2017 - 2022
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Press Mentions

  • Copper Depletion Combats Metastatic Recurrence in High-Risk TNBC
    Copper Depletion Combats Metastatic Recurrence in High-Risk TNBCSeptember 9th, 2024
  • This Clinical Trial Is Testing a Pill for Triple-Negative Breast Cancer
    This Clinical Trial Is Testing a Pill for Triple-Negative Breast CancerAugust 27th, 2024
  • Post-ASCO News Alert: AstraZeneca’s/Merck’s Lynparza Use in Niche HR+ gBRCA-Mutant Breast Cancer Subgroup Could Compete with Verzenio
    Post-ASCO News Alert: AstraZeneca’s/Merck’s Lynparza Use in Niche HR+ gBRCA-Mutant Breast Cancer Subgroup Could Compete with VerzenioJune 21st, 2021
  • Join now to see all

Grant Support

  • Therapeutic targeting of the tumor microenvironment in triple negative breast cancer patients at high risk of relapse and preclinical models of lung metastasesDARTMOUTH-HITCHCOCK CLINIC2025–2030
  • Copper-mediated metabolic reprogramming and ECM alterations in TNBC metastasisWEILL MEDICAL COLL OF CORNELL UNIV2021–2026

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: